GV20 Therapeutics Announces Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation to Develop Novel Antibody-Drug Conjugates

NEWTON, Mass., March 26, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this collaboration, MTPC will leverage GV20's antibodies, which are specifically directed against novel tumor antigen targets discovered through GV20's proprietary STEAD AI platform, to generate potentially first-in-class antibody-drug conjugates.

"This agreement underlines the strength of GV20's STEAD platform in discovering novel tumor targets and human-derived antibodies." said Ying Gong, Ph.D., Chief Business Officer of GV20. "We are excited to partner with MTPC, leveraging their deep expertise in linker-payload technology and therapeutics development, to advance innovative antibody-drug conjugate (ADC) therapies against these novel targets."

Under the terms of the agreement, GV20 will receive an upfront payment and is eligible for milestone payments. MTPC will receive an exclusive right to negotiate a license to these antibodies during the collaboration term.

ABOUT GV20 THERAPEUTICS

GV20 Therapeutics is a clinical-stage biotech company dedicated to developing next-generation cancer biotherapeutics. GV20's AI-driven STEAD platform integrates massive B cell repertoire data, -omics data, and advanced AI models to provide deep insights into the tumor microenvironment and uncover targets and therapeutic antibodies that elude other approaches. GV20's pipeline includes best-in-class and first-in-class monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs). The lead program, GV20-0251, is an AI-designed, first-in-class, fully human monoclonal antibody targeting the novel immune checkpoint IGSF8 (Li et al, Cell 2024). Preclinical studies show that anti-IGSF antibodies enhance NK cell cytotoxicity, dendritic cell antigen presentation, and T cell activation, both alone and with anti-PD1. In a Phase 1/2a trial (NCT05669430) for advanced solid tumors, GV20-0251 demonstrates safety and promising monotherapy efficacy. GV20-0251 advanced from target discovery to IND in three years, marking a paradigm shift in AI-driven antibody drug discovery.

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

Business Contact
Ying Gong, Ph.D., CBO
[email protected]

SOURCE GV20 Therapeutics